Status:
COMPLETED
Irisin Levels in Patients With Charcot-Marie-Tooth (CMT) Disease
Lead Sponsor:
University of Bari
Conditions:
Charcot-Marie-Tooth Disease
Eligibility:
All Genders
Brief Summary
Irisin is an exercise-mimetic myokine secreted by skeletal muscle. Compelling evidence in animal models and humans showed that Irisin prevents onset of musculoskeletal atrophy and its low serum levels...
Detailed Description
Currently, there are no effective treatment approaches for CMT other than treating symptoms with medications such as nonsteroidal anti-inflammatory drugs that provide relief of lower back or leg pain....
Eligibility Criteria
Inclusion
- Definitive diagnosis of Charcot-Marie-Tooth disease
Exclusion
- osteoporosis
- intestinal malabsorption
- chronic inflammatory diseases
- chronic renal failure
- severe heart failure
- neoplastic diseases
Key Trial Info
Start Date :
November 2 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 30 2020
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT04786522
Start Date
November 2 2019
End Date
December 30 2020
Last Update
March 10 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Policlinic Hospital
Bari, Italy, 70124